Dubuque Bank & Trust Co. decreased its position in Celgene Corporation (NASDAQ:CELG) by 5.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,627 shares of the biopharmaceutical company’s stock after selling 2,824 shares during the period. Celgene Corporation accounts for 1.3% of Dubuque Bank & Trust Co.’s investment portfolio, making the stock its 25th largest position. Dubuque Bank & Trust Co.’s holdings in Celgene Corporation were worth $5,802,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Motco increased its stake in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Carroll Financial Associates Inc. increased its stake in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the period. Barnett & Company Inc. increased its stake in Celgene Corporation by 18.3% in the third quarter. Barnett & Company Inc. now owns 1,130 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 175 shares during the period. Reilly Financial Advisors LLC increased its stake in Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 161 shares during the period. Finally, WealthTrust Arizona LLC increased its stake in Celgene Corporation by 26.1% in the first quarter. WealthTrust Arizona LLC now owns 1,213 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 251 shares during the period. 78.24% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Shares of Celgene Corporation (NASDAQ CELG) traded up 1.45% during trading on Friday, reaching $122.36. The company’s stock had a trading volume of 7,424,941 shares. Celgene Corporation has a 52-week low of $94.42 and a 52-week high of $127.64. The firm’s 50-day moving average is $119.11 and its 200 day moving average is $119.63. The company has a market cap of $95.54 billion, a PE ratio of 45.95 and a beta of 1.82. Celgene Corporation also was the recipient of unusually large options trading on Friday. Stock traders acquired 1,785 call options on the stock. This represents an increase of 104% compared to the typical volume of 873 call options.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.21. Celgene Corporation had a return on equity of 70.94% and a net margin of 18.32%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.04 billion. During the same period in the prior year, the company earned $1.32 earnings per share. The company’s quarterly revenue was up 17.8% on a year-over-year basis. On average, equities research analysts predict that Celgene Corporation will post $7.29 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/06/18/dubuque-bank-trust-co-cuts-position-in-celgene-co-celg-updated-updated.html.

A number of research analysts have recently commented on CELG shares. Jefferies Group LLC set a $154.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Saturday, May 13th. Oppenheimer Holdings, Inc. set a $148.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Wednesday. Cantor Fitzgerald set a $159.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Saturday, February 18th. BidaskClub raised Celgene Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday. Finally, Cowen and Company reissued an “outperform” rating and set a $150.00 price objective on shares of Celgene Corporation in a report on Wednesday, March 8th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $139.49.

In other news, Director James J. Loughlin sold 9,250 shares of the stock in a transaction on Monday, May 1st. The stock was sold at an average price of $124.00, for a total value of $1,147,000.00. Following the completion of the transaction, the director now directly owns 32,169 shares in the company, valued at approximately $3,988,956. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders have sold 28,068 shares of company stock valued at $3,459,768 over the last 90 days. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.